Modified

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

Modified Independent and Landing International Announce Partnership to Sponsor the Groundbreaking "State of Accessibility in Beauty" Report

Retrieved on: 
Tuesday, April 2, 2024
Modified, Partnership, Disability, International, Movement, User-centered design

to sponsor the "State of Accessibility in Beauty" industry report.

Key Points: 
  • to sponsor the "State of Accessibility in Beauty" industry report.
  • "Our vision at Modified Independent is to create a world where self-care is accessible to all," said Dr. Bae.
  • "This partnership with Landing and our joint sponsorship of the 'State of Accessibility in Beauty' report is a crucial step towards realizing that vision."
  • The "State of Accessibility in Beauty" report will be released on April 2, 2024, and available through this link.

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Retrieved on: 
Tuesday, February 20, 2024
Orion Corporation, Pulmonary hypertension, Heart failure, Therapy, IP, Modified, Pharmaceutical industry

Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire world

Key Points: 
  • Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire world
    Improved net sales royalty rate structure, now ranging from high single-digit to low-teen percentages.
  • “We are delighted to enter into this important amendment to our license from Orion.
  • We have achieved a key corporate objective by expanding our development, IP, and commercial territory rights for levosimendan beyond North America,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.
  • “Our efforts to secure global commercial rights and leverage the additional potential IP protection around the world enable us to build significant shareholder value as we advance levosimendan into Phase 3 testing,” said Mr. Giordano.

New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life

Retrieved on: 
Monday, December 11, 2023
Oncology, Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Well, Mycosis fungoides, Organ, Neuropsychological test, CTCL, Cutaneous T-cell lymphoma, Central Statistics Office (India), Disease, Skin, Eastern Cooperative Oncology Group, Modified, Patient, Itch, Bivariate, Lymph, KKI, Neoplasm, Blood, ECOG, Cancer, ANOVA, Erythroderma, Female, Quality of life, Children's Oncology Group, Nursing, Medical imaging

Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.

Key Points: 
  • Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.
  • Bivariate analysis (t-tests and ANOVA) was used to identify demographic and medical history variables that had a relationship with HRQL.
  • LASSO (least absolute shrinkage and selection operator) regression analysis was used to identify factors that may drive poor HRQL.
  • In multivariate analysis, worse HRQL was associated with being younger, female, moderate or severe pruritus and impaired function (as measured by ECOG PS).

New Post Hoc Analysis from MAVORIC Trial Sheds Light on Burden of Cutaneous T-cell Lymphoma on Health-related Quality of Life

Retrieved on: 
Monday, December 11, 2023
Well, American Society of Hematology, Mycosis fungoides, Organ, Neuropsychological test, CTCL, Cutaneous T-cell lymphoma, Central Statistics Office (India), Disease, Skin, Eastern Cooperative Oncology Group, Modified, Patient, Itch, Bivariate, Lymph, Neoplasm, TSE, Blood, ECOG, Cancer, ANOVA, Erythroderma, Society, Female, Quality of life, Children's Oncology Group, Kyowa Kirin, B-cell lymphoma

PRINCETON, N.J., Dec. 11, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, today announced health-related quality of life (HRQL) findings from a post hoc analysis of the MAVORIC trial in patients with mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). Researchers analyzed baseline data collected prior to initiation of study treatments and found the symptoms of advanced MF/SS affected HRQL across all domains, with poorer HRQL associated with being younger in age, female, having moderate or severe itching, and impaired function as measured by the Eastern Cooperative Oncology Group performance status (ECOG PS).

Key Points: 
  • Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical," said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.
  • Bivariate analysis (t-tests and ANOVA) was used to identify demographic and medical history variables that had a relationship with HRQL.
  • LASSO (least absolute shrinkage and selection operator) regression analysis was used to identify factors that may drive poor HRQL.
  • Researchers concluded that assessing a patient's disease concerns may help guide treatment goals and therapeutic choice.

Williams Reports Strong Third-Quarter Results

Retrieved on: 
Wednesday, November 1, 2023
Trucking, Other Energy, Logistics, Supply Chain Management, Oil, Gas, Transport, Energy, Other Transport, Adjustment, JV, Sale, Au Sable, Weather, Haynesville, Rocky Mountains, NGL, EBITDA, News, Modified, Discovery, Acquisition, Opal, MountainWest Sports Network, Ethane, Webcast, Central Time, NYMEX, Marketing, Barnett, Bookkeeping, Fine chemical, Petroleum, Broadcasting

In the third quarter, Williams sold its Bayou Ethane system for $348 million in cash, representing a last-twelve-month multiple over 14x Adjusted EBITDA.

Key Points: 
  • In the third quarter, Williams sold its Bayou Ethane system for $348 million in cash, representing a last-twelve-month multiple over 14x Adjusted EBITDA.
  • Williams has also agreed to purchase KKR’s 50 percent ownership interest in Rocky Mountain Midstream, resulting in 100 percent ownership of Rocky Mountain Midstream for Williams.
  • Williams' Third-Quarter 2023 Materials to be Posted Shortly; Q&A Webcast Scheduled for Tomorrow
    Williams' third-quarter 2023 earnings presentation will be posted at www.williams.com .
  • A webcast link to the conference call will be provided on Williams’ Investor Relations website.

VERB Reports Record-Breaking FY 2022 SaaS Revenue

Retrieved on: 
Monday, April 17, 2023
Software as a service, Total Digital Access to the League of Nations Archives Project, Modified, Form 10-K, GAAP, History, SALT, Wind, State Administrative Expenses, EBITDA, Cost, Administration, Depreciation, Research, Asset, Total, Arms industry, Retail, Cryptocurrency, Food delivery

MARKET.live general and administrative expenses limited to less than $2.0 million

Key Points: 
  • MARKET.live general and administrative expenses limited to less than $2.0 million
    Year End Cash position $2.4 million, plus $1.6 million in receivables and pre-paid expenses.
  • Non-GAAP adjustments to our results prepared in accordance with generally accepted accounting principles (“GAAP”) are itemized below.
  • You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis.
  • In addition to our results under GAAP, we present Modified EBITDA as a supplemental measure of our performance.

Clip Money Inc. Announces Amendment to Previously Announced Convertible Note Financing

Retrieved on: 
Thursday, April 13, 2023
Unit, Minority, Finder, Note, Indian stock exchange, MI, Modified, Private, Conversion, CAD, Sale, Private placement, Public expenditure, Prospectus, Acquisition, Warrant, Finance Secretary (India), Legislation, Security (finance), Life insurance, Corporation

Each Note Unit will consist of one 12% unsecured convertible note with a principal amount of $1,000 (each a “Note”) and 1,000 common share purchase warrants of the Company (each, a “Warrant”).

Key Points: 
  • Each Note Unit will consist of one 12% unsecured convertible note with a principal amount of $1,000 (each a “Note”) and 1,000 common share purchase warrants of the Company (each, a “Warrant”).
  • Each Note issued under the Modified Offering will be due and payable on the date that is 36 months from the date of issuance (the “Maturity Date”).
  • On the Maturity Date, payment of the principal amount of each Note plus accrued and unpaid interest thereon will be satisfied in cash.
  • Closing of the Modified Offering is subject to Clip Money obtaining all necessary corporate and regulatory approvals, including approval of the TSXV.

Pea Starch Market to Reach $307.4 Million by 2029 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

Retrieved on: 
Monday, January 16, 2023
Meat, Pesticide, Animal feed, Meal, COVID-19, Ebro Foods, Urban, Research report, Paper, Binder, Pulp and paper industry, Food, The Non-GMO Project, Work, Geography, Starch, Convention (norm), Foodservice, Dairy, Thickening agent, Agent handling, Growth, LTD, Prevalence, Food industry, Urbanization, Ingredion, Degenerative disease, United Nations, Modified, Impact, Flour, Legume, Fast food, Agriculture, Nature, Stabilizer

Based on nature, the pea starch market is segmented into organic pea starch and conventional pea starch.

Key Points: 
  • Based on nature, the pea starch market is segmented into organic pea starch and conventional pea starch.
  • Quick Buy – Pea starch Market - Global Opportunity Analysis And Industry Forecast (2022-2029), Research Report: https://www.meticulousresearch.com/Checkout/18927167
    Based on type, the pea starch market is segmented into native pea starch and modified pea starch.
  • In 2022, the native pea starch segment accounted for the largest share of the pea starch market.
  • Based on function, the pea starch market is segmented into thickener & gelling agent, binder, stabilizers, disintegrants, and other functions.

Pea Starch Market to Reach $307.4 Million by 2029 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

Retrieved on: 
Monday, January 16, 2023
Meat, Pesticide, Animal feed, Meal, COVID-19, Ebro Foods, Urban, Research report, Paper, Binder, Pulp and paper industry, Food, The Non-GMO Project, Work, Geography, Starch, Convention (norm), Foodservice, Dairy, Thickening agent, Agent handling, Growth, LTD, Prevalence, Food industry, Urbanization, Ingredion, Degenerative disease, United Nations, Modified, Impact, Flour, Legume, Fast food, Agriculture, Nature, Stabilizer

Based on nature, the pea starch market is segmented into organic pea starch and conventional pea starch.

Key Points: 
  • Based on nature, the pea starch market is segmented into organic pea starch and conventional pea starch.
  • Quick Buy – Pea starch Market - Global Opportunity Analysis And Industry Forecast (2022-2029), Research Report: https://www.meticulousresearch.com/Checkout/18927167
    Based on type, the pea starch market is segmented into native pea starch and modified pea starch.
  • In 2022, the native pea starch segment accounted for the largest share of the pea starch market.
  • Based on function, the pea starch market is segmented into thickener & gelling agent, binder, stabilizers, disintegrants, and other functions.